Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Benztropine(click to collapse)
1/4 selected
Benztropine
Cogentin
Anticholinergic
FDA-approved indications
- An adjunct in the therapy of all forms of parkinsonism
Off-label uses
- Dystonia (drug-induced)
- Drooling/sialorrhea
Half-life~12 hours
Decision GuideWhen to pick each / when to consider an alternative
Benztropine
Consider when
- Acute dystonic reaction — IM/IV benztropine provides rapid relief of acute dystonia within minutes; first-line treatment
- Drug-induced parkinsonism from antipsychotics — FDA-approved for EPS; effective for tremor, rigidity, and bradykinesia
- Parenteral administration needed for acute EPS — IM/IV formulation available (unlike trihexyphenidyl which is oral-only)
- Once- or twice-daily dosing preferred — longer t½ than trihexyphenidyl allows BID dosing; better adherence
- +1 more
Consider an alternative when
- Elderly patient — Beers Criteria avoid; cognitive impairment, falls, urinary retention, constipation risk magnified
- Tardive dyskinesia — anticholinergics may worsen TD; VMAT2 inhibitors (valbenazine, deutetrabenazine) are evidence-based alternatives
- High anticholinergic burden from other medications — additive anticholinergic toxicity; consider amantadine as non-anticholinergic alternative
- Narrow-angle glaucoma or BPH — anticholinergic contraindications; may precipitate acute angle closure or urinary retention
- +1 more
| Axis | Benztropine anticholinergic |
|---|---|
| CNS | |
Cognitive dulling / anterograde amnesia | |
| Autonomic | |
Anticholinergic burden | |
Urinary retention / hesitancy | |
| Sensory | |
Visual disturbances (blurred vision, diplopia, lens changes) | |
| Cardiac | |
Heart rate / tachycardia | |
| GI | |
Nausea / GI (general) | |
Constipation / GI hypomotility | |
| Drug-specific / distinctive axes | |
Hyperthermia / heat stroke (WARNING — potentially fatal) only in Benztropine | |